Scarica l'app Stockscreener
61.69
0.84%
-0.52
Pre-mercato:
61.73
0.04
+0.06%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$62.21
Aprire:
$61.985
Volume 24 ore:
6.75M
Relative Volume:
1.05
Capitalizzazione di mercato:
$24.06B
Reddito:
$4.30B
Utile/perdita netta:
$571.50M
Rapporto P/E:
43.19
EPS:
1.4285
Flusso di cassa netto:
$570.80M
1 W Prestazione:
+2.53%
1M Prestazione:
-12.28%
6M Prestazione:
-27.00%
1 anno Prestazione:
-20.74%
Intervallo 1D:
$61.42
$64.00
Intervallo di 1 settimana:
$58.28
$64.00
Portata 52W:
$54.11
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Confronta DXCM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
61.69 | 24.26B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
128.05 | 221.17B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
101.36 | 145.34B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
375.08 | 141.58B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
105.35 | 132.37B | 34.76B | 4.79B | 5.21B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
86.82 | 49.16B | 5.88B | 1.34B | 799.60M | 2.3489 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class ActionContact Lieff Cabraser - ACCESS Newswire
GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program - TradingView
Shareholders that lost money on DexCom, Inc.(DXCM) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - Morningstar
Morgan Stanley, Truist Cautious on DexCom (DXCM) Cites Weaker Gross Margins, Modest Q3 Beat - Insider Monkey
Carillon Eagle Mid Cap Growth Fund’s Views on Dexcom (DXCM) - Insider Monkey
Evercore Initiates Coverage on DexCom With In Line Rating, $68 Price Target - MarketScreener
Elanco, AMN Healthcare Services, Brookdale, DexCom, and Addus HomeCare Shares Skyrocket, What You Need To Know - Markets Financial Content
DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing - GlobeNewswire
DexCom, Inc. Class Action: The Gross Law Firm Reminds - GlobeNewswire
Lowey Dannenberg Notifies DexCom, Inc. (“DexCom” or the - GlobeNewswire
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Ademi & Fruchter LLP Investigates Claims of Securities Fraud against DexCom, Inc. - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Investors in DexCom, Inc. Should Contact The Gross Law Firm Before December 26, 2025 to Discuss Your RightsDXCM - Morningstar
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages DexCom, Inc. - GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM - GlobeNewswire Inc.
Kessler Topaz Meltzer & Check, LLP Notifies DexCom, Inc. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit - The Globe and Mail
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of DexCom, Inc. to Contact the Firm Today! - ACCESS Newswire
DXCM Announcement: Kessler Topaz Meltzer & Check, LLP Encourages DexCom, Inc. (DXCM) Investors to Contact the Firm About Securities Fraud Class Action Lawsuit - The Malaysian Reserve
Bank Julius Baer & Co. Ltd Zurich Sells 8,697 Shares of DexCom, Inc. $DXCM - Defense World
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know - Yahoo Finance
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DXCM LAWSUIT ALERT: Levi & Korsinsky Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NewMediaWire
DexCom, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsDXCM - MarketScreener
DexCom Inc. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages DexCom, Inc. - GlobeNewswire
DCXM DEADLINE ALERT: DexCom, Inc. Investors Urged to Contact Kirby McInerney LLP About Class Action Lawsuit - GlobeNewswire
Dexcom (DXCM) Valuation: Assessing Upside After FDA Clearance of Smart Basal Diabetes Device - Yahoo Finance
Levi & Korsinsky Notifies Shareholders of DexCom, Inc. (DXCM) of a Class Action Lawsuit and an Upcoming Deadline - GlobeNewswire
Dexcom Smart Basal Receives FDA Clearance for Personalized Basal Insulin Dosing - Pharmacy Times
DXCM Deadline Alert: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal - Finviz
Dexcom to Release G7 15 Day CGM Next Month - Medical Product Outsourcing
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States - GuruFocus
Dexcom G7 15 day continuous glucose monitoring system to launch on Dec. 1 in the United States - MarketScreener
Dexcom G7 15 Day Continuous Glucose Monitoring System To Launch On Dec. 1 In The United States - TradingView
The Gross Law Firm Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 26, 2025DXCM - PR Newswire
Is DexCom Inc. (DC4) stock cheap by valuation metricsQuarterly Profit Report & Free Technical Pattern Based Buy Signals - newser.com
FDA clearances: Dexcom, GE HealthCare, Zimmer Biomet, BrainsWay - Modern Healthcare
DexCom, Inc. $DXCM Shares Acquired by Artisan Partners Limited Partnership - Defense World
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit - Morningstar
Will DexCom Inc. (DC4) stock profit from AI boomWeekly Investment Recap & Technical Analysis for Trade Confirmation - newser.com
Can DexCom Inc. (DC4) stock sustain revenue momentumOil Prices & Long-Term Growth Stock Strategies - newser.com
Bragar Eagel & Squire, P.C. Urges Stockholders of DexCom, - GlobeNewswire
FDA clears Dexcom Smart Basal for insulin optimization - BioWorld MedTech
The Gross Law Firm Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming ... - Bluefield Daily Telegraph
The Gross Law Firm Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – DXCM - GlobeNewswire
Why DexCom Inc. stock is in analyst buy zoneJuly 2025 Recap & Capital Efficient Trade Techniques - newser.com
Dexcom Smart Basal wins FDA Clearance for Type 2 diabetes insulin support - Medical Economics
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.57%
1.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):